Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Researchers report on the outcomes of 12 patients who received intrathecal chemotherapy for the treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) between 2017 and 2023. The data suggest that early administration of intrathecal chemotherapy is feasible and is highly effective in the management of ICANS; however, larger studies are needed to validate these findings.